High-flying Novo Nordisk once again dials up its 2023 sales and profit expectations

High-flying Novo Nordisk once again dials up its 2023 sales and profit expectations

Source: 
Fierce Pharma
snippet: 

The popular diabetes med Ozempic and its sister weight-loss drug Wegovy are boosting Novo Nordisk to new highs again and again.

The Danish company now expects full-year sales to grow between 32% and 38% at constant exchange rates.